The FDA recently approved the Lucentis 0.5-mg prefilled syringe to treat patients with myopic choroidal neovascularization. Like the Lucentis 0.5-mg vial, the 0.5-mg prefilled syringe is also approved to treat patients with wet age-related macular degeneration and macular edema after retinal vein occlusion.
For more information, visit gene.com.
LENSAR’s Streamline III Upgrade
Streamline III, LENSAR’s new system upgrade, seeks to provide surgeons with the technology to better manage astigmatism and optimize patient outcomes. The new upgrade contains features that will optimize surgeon confidence, safety, efficiency and laser precision, says LENSAR.
Included in the upgrade’s features is a new wireless total corneal astigmatism data transfer, which provides more precise astigmatism treatment planning that may result in better postop results. LENSAR also introduces a new corneal incision-only mode with the Streamline III upgrade, allowing surgeons to perform laser corneal incisions independent of capsulotomy and fragmentation.
The Streamline III upgrade also includes other features designed to better manage astigmatism. These include: arcuate incision planning (allowing for one-touch incision planning); toric IOL power conversions (more precise reduction of residual corneal astigmatism); and iris registration and automatic cyclorotation adjustment (compensates for cyclorotation, eliminating the need for corneal ink marking).
For more information on the Streamline III upgrade, visit lensar.com/features.
OD-OS’s Navilas Laser System 577s
For surgeons looking to streamline laser-therapy planning, OD-OS’s Navilas 577s allows for physicians to digitally pre-plan the entire laser therapy based on fundus and diagnostic images.
The Navilas laser system 577s is a retinal photocoagulator that comes integrated with a digital fundus camera. According to OD-OS, the Navilas is used for the treatment of diabetic macular edema, proliferative diabetic retinopathy, subretinal neovascularization, retinal vein occlusion, lattice degeneration, retinal tears and retinal detachments. The Navilas is also used for both color and infrared imaging of the retina.
OD-OS adds that the Navilas offers focal treatments without a contact lens and infrared illumination, which enhances patient comfort. The company also says the device’s large field of view and assisted pattern positioning improve panretinal and focal treatments.
For more information on OD-OS’s Navilas 577s, visit od-os.com.